NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

A research team, affiliated with UNIST has unveiled soft self-standing protein hydrogels that selectively deliver drugs, ...

The television presenter, 52, revealed in 2022 she had been diagnosed with stage one breast cancer after doctors found a lump ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company” or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the United States Securities and Exchange Commission (SEC). In this filing, Processa Pharmaceuticals disclosed that a copy of a slide ...

Pancreatic enzyme replacement therapy (Pert) provides the enzymes people affected by pancreatic cancer need to absorb nutrients.